spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Chronic Myelogenous Leukemia 

 HSMN NewsFeed - 26 Aug 2022
Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Nov 2021
Kintara Announces Changes to Executive Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Sep 2021
Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2017
Mylan and Aspen Announce Launch of Generic Busulfex(R) Injection
Biopharmaceuticals Oncology Generics Product Launch
 HSMN NewsFeed - 22 Jun 2017
DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Apr 2016
FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Dec 2015
Syros Pharmaceuticals Appoints David A. Roth, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Feb 2014
Avillion Appoints Dr Allison Jeynes-Ellis as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jan 2013
New NCCN Guidelines for Patients(R) Available for Adolescents and Young Adults with Cancer
Biopharmaceuticals Devices Oncology
 HSMN NewsFeed - 18 Jan 2013
Pfizer’s Bosutinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or Intolerance To Prior Therapy In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Dec 2012
Amarantus BioScience Acquires Neurodegenerative Diagnostic Intellectual Property Portfolio from Power3 Medical Products
Biopharmaceuticals Diagnostics Neurology Acquisitions
 HSMN NewsFeed - 26 Oct 2012
Teva Receives Approval For SYNRIBO(TM) (Omacetaxine Mepesuccinate) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jan 2012
Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph+ Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2011
Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Sep 2011
DelMar Pharmaceuticals Receives FDA IND Approval to Begin Clinical Trials With A New Brain Cancer Treatment
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Aug 2011
New NCCN Patient Guidelines Help Patients Navigate the Maze of Breast Cancer Treatment Options
Oncology
 HSMN NewsFeed - 6 Dec 2010
Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jan 2010
Meda In-Licenses Exclusive Rights To Ceplene
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Oct 2009
MolecularMD Establishes New Operations Facility to Support Growth in Personalized Cancer Medicine Business
Diagnostics Oncology
 HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2009
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Aug 2008
Panacea Pharmaceuticals Announces Appointment of Suzanne Sensabaugh as Vice President, Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2008
Lilly to Acquire SGX Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 9 Jun 2008
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 May 2008
NCCN Previews Chemotherapy Order Templates(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2008
Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Dec 2007
Otsuka Pharmaceutical Acquires Rights to IV Busulfex From PDL BioPharma
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 20 Nov 2007
Vertex's Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Oct 2007
Tasigna(R) receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Oct 2007
INNOVIVE Pharmaceuticals Announces Receipt of FDA Orphan Drug Designation for Tamibarotene for the Treatment of Acute Promyelocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Sep 2007
INNOVIVE Pharmaceuticals Acquires Exclusive Rights to Develop and Commercialize Tamibarotene in Europe
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 17 Jul 2007
Panacea Pharmaceuticals Announces the Availability of LC Detect(sm), a Serum-Based Diagnostic Test for Lung Cancer
Diagnostics Oncology
 HSMN NewsFeed - 7 Jun 2007
INNOVIVE Pharmaceuticals Receives FDA Fast Track Designation for Tamibarotene for the Treatment of Acute Promyelocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jun 2007
Cytokinetics Announces the Presentation of Clinical Trials Data at the 2007 Annual Meeting of the American Society of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
INNOVIVE Pharmaceuticals Presents Additional Phase I Data on INNO-406 for Treatment of Gleevec-Resistant or Intolerant Chronic Myelogenous Leukemia at the American Society of Clinical Oncology Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2007
Panacea Pharmaceuticals Announces the Availability of PC Detect(sm) for Prostate Cancer Screening
Diagnostics Oncology
 HSMN NewsFeed - 20 Mar 2007
DOR BioPharma Forms orBec(R) Medical Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Feb 2007
Tapestry Pharmaceuticals Appoints Sandra L. Silberman, M.D., Ph.D. As Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Feb 2007
INNOVIVE Pharmaceuticals Appoints Angelo De Caro to Its Board of Directors and Audit Committee
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jan 2007
Panacea Pharmaceuticals Appoints Pamela Harris, MD, Vice President Medical and Clinical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jan 2007
INNOVIVE Pharmaceuticals Announces Receipt of FDA Orphan Drug Designation for INNO-406 for the Treatment of Chronic Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jan 2007
Avalon Pharmaceuticals Names Clinical Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Dec 2006
INNOVIVE Pharmaceuticals Presents Data on Oncology Drug Programs in Chronic Myelogenous Leukemia and Acute Myelogenous Leukemia at American Society of Hematology 48th Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
INNOVIVE Pharmaceuticals Acquires Exclusive North American Rights to Tamibarotene, a Treatment for Acute Promyelocytic Leukemia; Company to Initiate Pivotal Study in 2007
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 27 Nov 2006
Cytokinetics and GlaxoSmithKline Amend Collaboration and License Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 21 Sep 2006
Panacea Pharmaceuticals Announces Appointments of Christine L. Brauer, Ph.D. as Vice President, Regulatory Affairs; and Jefferey Jones, M.S., as Director of Quality
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Aug 2006
SGX Pharmaceuticals Discontinues Phase II/III Clinical Trial of Troxatyl in Third-Line Acute Myelogenous Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Aug 2006
Dacogen(TM) (Decitabine) for Injection Receives U.S. Orphan Drug Designation for Patients with AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Aug 2006
Dacogen(TM) (Decitabine) For Injection Receives European Orphan Drug Designation for Patients With AML
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Jul 2006
MGI PHARMA Announces License Agreement with Cilag GmbH, a Johnson & Johnson Company, for Dacogen(TM) (decitabine) for Injection
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 28 Jun 2006
Panacea Pharmaceuticals Announces Appointment of Stephen N. Keith, MD, MSPH as President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2006
Data From a Randomized Phase II Study of Dasatinib or 800 Mg/Day Imatinib- Mesylate (Gleevec(R)) Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2006
Cell Genesys Reports Long-Term Follow-Up Data From Phase 2 Trial of GVAX(R) Immunotherapy For Leukemia in Chronic Myelogenous Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 May 2006
MGI PHARMA Announces Commercial Availability of Dacogen(TM) (Decitabine) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 May 2006
U.S. FDA Approves Dacogen(TM) (Decitabine) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Apr 2006
St. Jude Unlocks Mystery of Very Aggressive Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Mar 2006
SGX Pharmaceuticals Announces Strategic Collaboration to Develop and Commercialize BCR-ABL Inhibitors for the Treatment of Chronic Myelogenous Leukemia (CML)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 13 Mar 2006
Cell Genesys to Present Data From Two GVAX(R) Cancer Immunotherapy Clinical Trials at 2006 ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Mar 2006
FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Dasatinib
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Feb 2006
Cepheid Initiates CE IVD Products in Europe With Launch of GeneXpert(R) System and Xpert BCR-ABL Monitor(TM) Assay
Diagnostics Oncology
 HSMN NewsFeed - 9 Feb 2006
Genzyme Launches Key Test to Monitor Gleevec(R) Resistance
Diagnostics Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jan 2006
Innovive Pharmaceuticals Licenses Potent Dual Bcr-Abl/Lyn Kinase Inhibitor
Biopharmaceuticals Oncology Licensing
Return to NewsFeed  

 Additional items found! 34

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 34 additional stories matching:
Chronic Myelogenous Leukemia
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.